A Critical Review of LET-Based Intensity-Modulated Proton Therapy Plan Evaluation and Optimization for Head and Neck Cancer Management

Wei Deng, PhD; Yunze Yang, PhD; Chenbin Liu, PhD; Martin Bues, PhD; Radhe Mohan, PhD; William W. Wong, MD; Robert H. Foote, MD; Samir H. Patel, MD; Wei Liu, PhD

1Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA
2Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China
3Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA

Abstract

In this review article, we review the 3 important aspects of linear-energy-transfer (LET) in intensity-modulated proton therapy (IMPT) for head and neck (H&N) cancer management. Accurate LET calculation methods are essential for LET-guided plan evaluation and optimization, which can be calculated either by analytical methods or by Monte Carlo (MC) simulations. Recently, some new 3D analytical approaches to calculate LET accurately and efficiently have been proposed. On the other hand, several fast MC codes have also been developed to speed up the MC simulation by simplifying nonessential physics models and/or using the graphics processor unit (GPU)–acceleration approach. Some concepts related to LET are also briefly summarized including (1) dose-weighted versus fluence-weighted LET; (2) restricted versus unrestricted LET; and (3) microdosimetry versus macrodosimetry. LET-guided plan evaluation has been clinically done in some proton centers. Recently, more and more studies using patient outcomes as the biological endpoint have shown a positive correlation between high LET and adverse events sites, indicating the importance of LET-guided plan evaluation in proton clinics. Various LET-guided plan optimization methods have been proposed to generate proton plans to achieve biologically optimized IMPT plans. Different optimization frameworks were used, including 2-step optimization, 1-step optimization, and worst-case robust optimization. They either indirectly or directly optimize the LET distribution in patients while trying to maintain the same dose distribution and plan robustness. It is important to consider the impact of uncertainties in LET-guided optimization (ie, LET-guided robust optimization) in IMPT, since IMPT is sensitive to uncertainties including both the dose and LET distributions. We believe that the advancement of the LET-guided plan evaluation and optimization will help us exploit the unique biological characteristics of proton beams to improve the therapeutic ratio of IMPT to treat H&N and other cancers.

Keywords: linear-energy-transfer; intensity-modulated proton therapy; relative biological effectiveness
Introduction

Particle (proton and heavy ion) radiation therapy is a rapidly evolving technology. Compared with conventional photon-based radiation therapy, particle therapy has a significantly lower entrance to peak dose ratio, since most of the particle energy is released near the end of its range (Bragg peak). This behavior offers improved conformal dose coverage of target volumes and reduces dose to organs at risk (OARs) in the low- to middle-dose range (eg, the low-dose bath effect) [1, 2], which potentially leads to less normal tissue damage and lowers the risk of secondary cancers. Meanwhile, from the radiobiology point of view, the high linear-energy-transfer (LET) behavior of particle therapy has less oxygenation dependency [3, 4] and can overcome the radioresistance of hypoxic tumor cells [5, 6].

Although the qualitative benefits of particle therapy are well known, there are still many challenges in its clinical application, such as the variable relative biological effectiveness (RBE) [7, 8]. RBE is defined as the ratio of doses to reach the same level of clinical endpoints by a radiation modality, such as proton therapy, as compared to Co-60 irradiation. Via RBE, we can take advantage of the extensive experience from photon treatment; otherwise extensive independent clinical data for particle therapy are required to generate dosimetric indices as a surrogate for potential clinical outcomes. Unfortunately, RBE of particle therapy has not been well quantified [7, 9–12] and is dependant on many factors, for example, LET, clinical endpoints, tissue type, fractionation scheme, patient-specific radiosensitivity, physical dose [7, 8], and the uncertainties in experimental measurements [13–18]. Some RBE models have been used in current clinical practice for both proton and heavy ion therapy.

For proton therapy, a fixed RBE of 1.1 is applied clinically, which likely oversimplifies the RBE model and underestimates RBE around high LET locations (eg, distal end of Bragg peak) [19] in proton therapy. An underestimation of RBE will potentially increase the risk of toxicities in the nearby OARs.

From now on, in our discussion we will focus on intensity-modulated proton therapy (IMPT), the most contemporary generation of proton therapy available in current clinical practice. However, many concepts and research reviewed here are highly relevant to other heavy ion therapy modalities as well. Although there are many uncertainties, RBE of protons monotonically increases with LET when all other parameters are held constant [13, 20]. For protons, when LET is high (around 10 keV/µm) near the distal end of the proton beam and in the corresponding lateral penumbra regions, owing to multiple Coulomb scattering [7], RBE can be much higher than 1.1 (around 1.5). There are reports [21–23] of an increasing risk of brainstem, lung, and brain injury treated by proton therapy with increasing LET, suggesting that the proton RBE can exceed 1.1 in vivo. Hence, it is essential to develop an LET-based plan evaluation and optimization method for proton therapy. This issue is especially relevant in cancer treatment of disease sites such as head and neck (H&N), where there are many OARs such as brainstem and optic-nerve structures in the proximity [24–26].

In this report, we will review and summarize some classic and recent studies including LET calculation methods (analytical and Monte Carlo [MC] simulation; “LET Calculation” section), use of LET in H&N plan evaluation and patient outcome study (“Use of LET in H&N Plan Evaluation and Patient Outcome Study” section), and LET-guided plan optimization and implementation (“LET-Guided Plan Optimization and Implementation” section) for H&N cancer treatment by IMPT.

LET Calculation

As discussed in the “Introduction” section, the LET value is a good surrogate of RBE [13, 20]. For any studies related to LET-guided plan evaluation and optimization in H&N irradiation, an accurate and sufficiently fast LET calculation method is required in clinical practice. We will briefly review 3 topics related to LET calculation in the following 3 subsections: (1) analytical methods versus MC simulations; (2) dose-weighted average (LET_d) versus fluence-weighted average (LET_f); and (3) macroscopic versus microscopic dosimetry.

Analytical Methods versus MC Simulations

Monte Carlo simulations [11, 27–30] are generally more accurate than analytical approaches, but require much longer calculation time if a general-purpose MC code is used (eg, Geant4 [27], MCNPX [31], FLUKA [32, 33], and TOPAS [34]). Recently, several groups have developed in-house and/or open-source fast MC codes and implemented them into clinical practice, for example, gMC [35], gPMC [36], FRED [37], and MCsquare [38, 39]. These fast MC codes either simplify physics models dedicated to proton dose calculation or are accelerated with the help of graphics processor unit (GPU) to significantly reduce the simulation time with reasonable accuracy. Some commercial treatment planning systems (TPSs) with fast MC calculation capability have recently been released for routine dose calculation (eg, RayStation [40], Eclipse [41]) [42].

Deng et al (2020), Int J Particle Ther
Meanwhile, some groups have also developed MC-based robust optimization [43, 44] and MC-based robustness evaluation [45]. Various techniques are used to score LET in MC simulations; for example, scoring LET using the ratio of energy deposition to step-length [10, 11, 46], using the prestep proton kinetic energy [28, 29], converting proton energy spectrum to LET spectrum [47–50], and so on. Granville and Sawakuchi [29] did a detailed comparison among different LET scoring methods and found LET_D varied more than LET_f, using different scoring methods.

On the other hand, analytical LET calculation methods [15, 51–56] have been used in clinical practice owing to their high efficiency, acceptable computational accuracy, and other historical reasons. The widely used 1D LET models [13, 51, 52] only consider the LET variation along the beam direction and assume uniform LET values in the lateral direction. Since the LET value will significantly increase in the lateral distance from the beam axis owing to the higher proportion of low-energy halo particles, the 1D LET models underestimate LET in the penumbra region [55, 56]. Unfortunately the nearby OARs are usually located within the dose penumbra regions, therefore the LET values are likely underestimated within OARs, which potentially results in unexpected toxicities.

To overcome this drawback, Hirayama et al [55] and Deng et al [56] introduced 3D LET calculation models, which consider the variation of LET in the lateral directions. Hirayama et al [55] use a dual-Gaussian LET calculation kernel, which models contributions from the primary and the halo components of the proton beam separately. Deng et al [56] introduced a hybrid 3D analytical LET_D calculation approach based on the convolution superposition method commonly used in the pencil beam dose calculation. An accurate 3D analytical LET kernel by fitting the MC-simulated LET distribution was used.

**Dose-Weighted Average (LET_D) versus Fluence-Weighted Average (LET_f)**

There are 2 approaches to calculate LET values. The first is called dose-weighted LET (LET_D), which uses the dose of every proton beamlet as the weighting factor to average LET value within each voxel. The LET_D (x, y, z) at the voxel (x, y, z) can be calculated as follows:

\[
\text{LET}_D(x, y, z) = \frac{\sum \varphi_E(x, y, z; E_j) \text{SP}(E_j) \Delta E_j}{\sum \varphi_E(x, y, z; E_j) \text{SP}(E_j) \Delta E_j},
\]

where \(\varphi_E(x, y, z; E_j)\) is the proton energy spectrum with an energy of \(E_j\), and \(\text{SP}(E_j)\) is the unrestricted stopping power of protons with an energy of \(E_j\). The other is called fluence-weighted LET (LET_f), which uses the fluence of every proton beamlet as the weighting factor to average LET values within each voxel (x, y, z) as follows:

\[
\text{LET}_f(x, y, z) = \frac{\sum \varphi_E(x, y, z; E_j) \text{SP}(E_j) \Delta E_j}{\sum \varphi_E(x, y, z; E_j) \text{SP}(E_j) \Delta E_j}.
\]

Although \(\text{LET}_D\) may have a better correlation with RBE, since \(\text{LET}_f\) tends to underestimate the biological effect, there are no rigorous comparisons to demonstrate which is superior.

Meanwhile, to be better correlated with biological effect, the kinetic energy of secondary \(\delta\)-rays should be taken into consideration, since this energy, although transferred from the primary particles, is not deposited locally and will not affect the local RBE. Hence, the restricted \(\text{LET}_D\), which takes off the kinetic energy of secondary \(\delta\)-rays, was discussed and compared with the unrestricted \(\text{LET}_D\) (ICRU 2016) in the literature [28, 57]. From the reported results, the restricted \(\text{LET}_D\) shows an apparent dependence with the cutoff energy. There is no clinical evidence so far to show that the restricted \(\text{LET}_D\) correlates with RBE better than unrestricted \(\text{LET}_D\).

**Macrodosimetry versus Microdosimetry**

The concept of LET commonly discussed in the literature and used in clinical practice is in the scope of macrodosimetry, which is either the dose- or fluence-averaged LET corresponding to the voxel size (eg, millimeter scale). This approach is relatively easy to implement and is efficient to calculate. However, the concept of LET in the domain of macrodosimetry might compromise the correlation of LET to the biological effects in the microscopic domain and cannot reflect the potentially higher LET/RBE values from the microscopic point of view (eg, micrometer scale), since cells are much smaller than the millimeter scale. Hence, several groups have introduced the dose-mean lineal energy [58–62] (a counterpart concept of LET in the scope of microdosimetry).
Since it considers the microscopically imparted energy patterns instead of the macroscopically voxel size averaging, the dose-mean lineal energy will likely reflect the biological effects better than LET. Several groups have developed a microdosimetric–kinetic model [59, 60] and the subsequent modification models [61, 62] to describe the microdosimetric biological effect due to protons. Recently, models to calculate dose-mean lineal energy [57, 63, 64] have been developed and proposed to be used for the microscopic biophysical optimization [65, 66] in particle therapy. In the following section, we will give a more detailed review of different LET-related RBE models and their applications in plan evaluation and patient outcome study for IMPT to treat H&N cancer.

Use of LET in H&N Plan Evaluation and Patient Outcome Study

Relative Biological Effectiveness—as a Function of LET

Since proton LET increases at the distal end and RBE has a strong correlation with LET value, LET has been considered as one of the key factors for determining the possible variable RBE in proton therapy. A variety of LET-related RBE models have been proposed, including phenomenological models [8,13–16,46,67–73], which are mostly based on linear-quadratic models, and mechanistic models, such as the microdosimetric-kinetic model [60], the local effect model [74–76], and the repair-misrepair-fixation model [77]. We refer our readers to previous reviews for details of these models and their comparisons [7, 78, 79].

While these models were derived from multiple measurements of various biological endpoints, including in vitro ones such as clonogenic cell survival and DNA breaks, as well as in vivo ones such as those from small animals, we will exclusively focus our discussion on recent studies that use clinical data as the biological endpoints for dosimetric study of IMPT plan evaluation and for patient outcome study in patients with H&N cancer.

Dosimetric Study Using LET for IMPT Plan Evaluation

Dosimetric evaluation of LET has been increasingly implemented in proton centers as a second check tool for IMPT. Typically, an analytically calculated or MC-simulated LET distribution of a treatment plan is generated for review. Physicians or physicists would evaluate the biological effects of the IMPT plan either by checking the overlapping volume of both high dose and high LET to avoid the overlap of dose and LET extremities in OARs, or by assessing the biological dose distribution derived from dose and LET distributions according to different RBE models. The Figure shows the LET distribution of a pediatric patient with skull base cancer treated by IMPT. High LET values above 6 keV/μm (shown as colorwash) were observed within brainstem in the original plan (left column) during the LET-guided plan evaluation for this patient. We therefore generated a new plan by using different beam angles (indicated as red arrows in the Figure) to minimize the high LET in brainstem. With similar dose distributions, the final plan (right column) displayed significant reduction of high LET distribution within brainstem. Currently this LET-guided plan evaluation has been routinely performed for every patient treated by IMPT at our institution.

Ideally, this plan evaluation procedure relies on (1) accurate and fast calculation of LET distributions (as discussed in “LET Calculation” section); (2) accurate biological dose calculation according to LET-related RBE models, and (3) reliable LET-related volume constraints (as dose volume constraints [DVCs] widely used in radiation therapy for decades). However, the last 2 criteria are currently unavailable in clinics, thus the second check is entirely based on estimation and experience from physicians and physicists.

Multiple studies have been carried out to evaluate the dosimetric effects of different RBE models in passive scattering proton therapy [80], and IMPT plans for numerous tumor sites including H&N [81–85], thorax [84, 86], liver [81], prostate [84, 87, 88], and craniospinal irradiations [89]. Tilly et al [68] first reported the influence on the dose volume histograms after RBE correction for a patient with hypopharynx cancer. Carabe et al [81] studied the impact of tissue-related parameter $\alpha/\beta$ and fractionations to biological dose, and revealed significant RBE uncertainties in critical structures for the central nervous system malignancies.

Comparison of different variable RBE models and evaluation of their influence have been studied in 2 clinical cases [82]. Giantsoudi et al [83] systematically studied LET and RBE for patients with medulloblastoma (111 patients). Another systematic study [84] was carried out for comparison of fixed versus variable RBE (including 80 patients with brain tumor and 128 with H&N cancer) with a variety of RBE models. Both studies indicated increased RBE doses at nearby OARs, compared to that using fixed RBE of 1.1. In addition, compared to planning target volume (PTV)–based optimization, robust optimization plans showed that dose distributions calculated with fixed-RBE of 1.1 were closer to the biological doses calculated with variant RBE.
models [85]. All these studies revealed dosimetric uncertainties of using different RBE models, as well as possible interpatient variations when applying RBE models. However, there is no consensus so far as to which model is better in RBE estimation.

**Patient Outcome Study Using LET in H&N IMPT**

Despite numerous in vitro measurements and several in vivo studies that have been performed, it is unclear whether the derived RBE models are applicable to clinical patient outcomes as the biological endpoint. In fact, clinical investigations showed inconclusive results regarding the impact of LET in patient outcomes. Sethi et al [90] pioneered the study of the LET effect on tumor recurrence of medulloblastoma. No correlation between regions of disease recurrence and low LET was observed in 16 patients with tumor relapse. The complication of central nervous system injury over a similar patient cohort was also investigated [83]. Although elevated LETs were observed in 10 injured areas that were identified and contoured with the help of magnetic resonance imaging (MRI) after the treatment by IMPT, no significant correlation was observed between the injury sites and the high RBE value. Note that both studies compared the calculated RBE values at the recurrence/complication regions. The analysis might be affected by the uncertainties in the RBE model calculation and the statistical analysis, since the conclusions were derived simply from the mean value.

Other studies have evaluated the correlation of patient outcomes with the local LET distributions. In a study of 34 pediatric patients with ependymoma, the treatment responses of voxels at the injured sites (indicated by image changes in the follow-up MRI scans) were assessed and modeled with a linear combination of the dose and LET [23]. The strong correlation between the response and the linear combination of the dose and LET strongly suggested a variable proton RBE in clinical practice. This finding was further supported by an analysis of asymptomatic lung fibrosis in chest-wall patients [22]. Results strongly suggested that the proton RBE exceeds 1.1, resulting in increase in lung fibrosis. A similar conclusion was drawn from recent studies in complications of radiation-induced cerebral vasculopathy in pediatric patients with craniopharyngioma [91] and multiple complications associated with intracranial tumors [92]. These findings were consistent with a variable RBE in vivo.

All the patient outcome studies summarized here exclusively rely on accurate contours of local injury/toxicity regions or functional regions at suborgan level that are typically obtained from the follow-up computed tomography and MRI images. Voxelwise tissue responses are correlated with the dose and LET values. In recent studies of glioma [93, 94], multivariable logistic regression models were established, with inputs not only from the dose and LET, but also from the interaction term such as the product of the dose and LET; and anatomy-related variables, such as the labeling of periventricular region, which indicates the proximities to the segmented ventricles as a risk factor. From this approach, a high correlation was observed in local complications of radionecrosis and late brain toxicities in relation to these factors. Moreover, a patient-level normal tissue complication probability (NTCP) model can be built with the voxel-level multivariate regression method by assuming that the relevant OARs are serial organs in the complication probability modelling [95]. This 2-level model achieved good local complication prediction and good NTCP models in the patient population for late radiation-induced contrast-enhancing brain
lesions of a cohort of 110 patients with glioma. These recent works have provided direct clinical evidence that RBE increases significantly with LET. Thus various LET-guided plan optimization approaches have been proposed to mitigate the negative impact of high RBE/LET in OARs, as reviewed in the following section.

**LET-Guided Plan Optimization and Implementation**

Various LET/RBE-guided plan optimization approaches have been proposed. Some pioneering works have been summarized here. Bassler et al [96] introduced the LET-painting technique in water phantom studies by using different irradiation modalities and beam configurations. The proton and carbon ion treatment planning system (TRIP) was used to yield treatment plans in conjunction with the in-house–developed software package “pytrip” [96]. The results demonstrated that similar dose distributions might have significantly different LET distributions. Grassberger et al [10] first investigated the LET distributions in patients by using MC simulations. The research version of KonRad generated 3-dimensional modulation IMPT and distal edge tracking IMPT [10]. Their results demonstrated that IMPT could have different LET distributions with clinically equivalent dose distributions, and the preselection of beam spots could be incorporated into the inverse-planning optimization to yield a superior LET distribution [10].

In the early stage of LET-guided optimization development, 2-step IMPT optimization methods were proposed to achieve a superior LET distribution [8, 97]. In the first step, dose distribution was optimized to meet current clinical requirements, and LET distribution was modified in the following step. Unkelbach et al [8] proposed a 2-step IMPT optimization scheme. The initial IMPT plans were optimized on the basis of physical dose, and then a prioritized optimization was used to modify the LET distribution and limit the degradation of physical dose distribution in the initial plan. Giantsoudi et al [97] also presented a dose-based multicriteria optimization method, which was integrated into the in-house treatment planning system (Astroid), to produce multiple IMPT treatment plans for navigating the Pareto-optimal space. In the second step, dose and LET distributions were calculated with the TOPAS (tool for particle simulation) MC method to facilitate the decision-making process [97]. Both methods were able to achieve superior LET distributions while maintaining equivalent dose distributions.

Instead of 2-step optimization, recent studies aimed to simultaneously optimize dose and LET distribution in the inverse planning for proton therapy [17, 73, 98–103]. Wan Chan Tseung et al [35, 73] developed a fast and accurate GPU-based MC method for LET-guided plan optimization in IMPT [73]. The LET distribution was integrated into a GPU-accelerated IMPT optimizer, which allowed the escalation of the target biological dose [73]. Cao et al [98] added 2 constraint terms for maximizing target LET and minimizing OAR LET in the cost function for optimization. Charnes and Cooper variable transformation was used to reformulate the original quasiconvex problem—which required sophisticated linear fractional programming—to a linear programming problem. The approach used by Cao and colleagues [98] did not use dose-volume/LET-volume constraints owing to the limitation of linear programming [104, 105], thus the determination of priority factors for dose and LET constraint terms was required. To customize the optimization in a user-friendly way, Inanîwa et al [101] used the summation of least-square terms in the dose- and dose-weighted-LET–based cost function. The customized treatment planning system (IMPACT) allowed the dose-volume and LET-volume constraints independently [101]. In summary, the 1-step optimization allowed for dose and LET optimization simultaneously, which could search in a larger solution space than the 2-step optimization method, possibly leading to better-quality IMPT plans.

Proton therapy is very sensitive to range and setup uncertainties. Without considering these uncertainties, both the delivered dose and LET could be significantly degraded compared to the planned ones. Robust optimization is an efficient way to hedge against the negative impacts of the range and setup uncertainties [1, 2, 17, 102, 106–122]. An et al [17] extended the voxelwise worst-case robust optimization by adding constraint terms to restrict the biological effect of LET in OARs. The unconstrained convex programming problem was solved by the L-BFGS (limited-memory Broyden-Fletcher-Goldfarb-Shanno) algorithm in a parallel computation environment [17]. Similarly, Bai et al [99] added constraint terms of biological effects for both OARs and targets in voxelwise worst-case robust optimization to maximize the biological effect itself and the robustness of biological effects. The new model reduced the biological effects in OARs and the variations of biological effects in targets and normal tissues [99]. Recently, Liu et al [102] developed LET-guided robust optimization (LETRO), which simultaneously minimized the LET in OARs, maximized LET in targets, and considered the range and setup uncertainties. The proposed LET-volume constraints provided a user-friendly way for treatment planning, which is similar to DVCs widely used for decades in radiation therapy treatment planning. Compared with the conventional voxelwise worst-case robust optimization, LETRO slightly escalated the target LET and reduced the OAR LET by slightly sacrificing plan quality and plan robustness for H&N cancer [102]. It is worth noting that only a few studies directly used LET objectives in the cost function [97, 98, 101, 102].
other studies, LET-related biological terms were used as an indirect indicator of LET in the optimization, including LET-weighted dose [8], biological surrogate [17], biological dose [73], biological component [99], and proton track ends [103].

Since the LET peak appears beyond the Bragg peak of proton beams, the optimization of proton beam angles and proton spot locations could render a superior LET distribution [97, 100, 103]. Traneus et al [103] used the location of the proton track-ends objectives in the IMPT treatment plan optimization. The method did not introduce additional complexity by using the LET calculation, LET-weighted dose, or LET-RBE interrelationship, but allowed for LET increase in target and LET reduction in OARs without sacrificing physical dose distribution. Bai et al [100] proposed a distal-edge avoidance-guided optimization method. Proton spots were categorized into 4 groups on the basis of topologic relationship among the peak position of LET-weighted dose, target location, and OAR location. The simplified calculation of peak position of LET-weighted dose used a certain distance away from the proton spots along the beam direction [100]. Then different groups of spots would use different penalty weights in the optimization [100]. Both studies optimized the proton spot locations instead of the LET-related objectives in the IMPT inverse treatment planning and achieved a superior LET distribution in both target and OARs [100, 103].

Discussion and Future Work

During the last 10 years, significant progress has been made in LET-related research in proton and heavier-particle therapy with regard to LET calculation, LET-guided plan evaluation, and LET-guided optimization. Many in vitro and in vivo studies have demonstrated the importance of the LET and variation of RBE in proton therapy, especially for H&N cancer. Recently, the TG-256 report [19] suggested assessing the potential clinical consequences, based on LET and recommended LET-guided optimization in IMPT.

In this review, we have focused on the advantages and disadvantages of different LET calculation methods from the points of view of accuracy, efficiency, and the relevance to biological effects in proton therapy. Highly accurate and efficient LET calculation methods based on either analytical methods or MC simulations are now available for clinical use, with the fast adoption of these methods in the commercial TPSs in the near future.

Currently, standard practice in most proton centers only checks for overlap of high dose and high LET in nearby OARs during the LET-guided IMPT plan evaluation with the goal of minimizing the overlap region. This simple method works relatively well although the thresholds of high dose and high LET are not based on clinical outcome. The LET-guided plan evaluation and patient outcome studies are done only in some academic centers. However, we expect that this will become the standard practice for IMPT to treat H&N cancer in the next 5 years. As more patient outcome data using IMPT become available and more LET-related patient outcome studies are performed, we believe that some LET-related volume constraints just as DVCs derived from QUANTEC [123] for plan evaluation purely based on the dose distribution will become available. The LET-related volume constraints can be used for plan evaluation and to predict the potential clinical consequences of IMPT plans in all disease sites with OARs abutting targets.

Today, no clinical studies with LET-guided optimization have been reported. It is important to consider the impact of uncertainties in LET-guided optimization (ie, LET-guided robust optimization) in IMPT, since IMPT is sensitive to uncertainties including both the dose and LET distributions. While some commercial TPSs such as the research version of RayStation (RayResearch Laboratories, Stockholm, Sweden) and some in-house-developed TPSs have LET-guided robust optimization implemented, more experience is needed before LET-guided robust optimization in IMPT can be adopted in clinical practice routinely. The relevant experience can also be used to treat some other disease sites as in LET-guided plan evaluation. More importantly, we can incorporate the LET-related volume constraints into the LET-guided robust optimization to achieve the patient-specific precision proton therapy for H&N cancer when the LET-related volume constraints are available. More research in this direction is urgently needed.

Accounting for increased biologic effectiveness of proton therapy in the treatment of H&N cancer is an unsolved problem. There is near universal agreement that the current approach of applying a fixed RBE of 1.1 is insufficient to prevent unwanted side effects of proton therapy and to model patient outcomes accurately. Furthermore, it is unclear whether any RBE model, which relies solely on physical dose, LET, and fractionation scheme, with the possible addition of some cell/tissue parameters, can accurately reflect the clinical reality of H&N cancer treatment with protons. What may be needed instead is a phenomenologic disease site– and organ-specific patient outcomes–oriented model that forgoes the computation of an equivalent photon dose along the lines of RBE, and based on physical dose, LET, fractionation scheme, and other factors,
directly predicts probabilities for tumor control and healthy-tissue complication. Owing to the complexity of the problem at hand, such a model would require an artificial intelligence–based algorithm, training sets of several hundred if not thousands of cases per organ per disease site, and possibly stratification by known risk factors such as concurrent chemotherapy and other unknown risk factors. These unknown risk factors could be systematically explored in this approach.

We believe that the advancement of LET-guided plan evaluation and optimization will help us exploit the unique biological characteristics of proton beams to further improve the therapeutic ratio of IMPT to treat H&N and other cancers.

### ADDITIONAL INFORMATION AND DECLARATIONS

**Conflicts of Interest:** Wei Liu, PhD, reports grants from National Institutes of Health/National Cancer Institute, Arizona Department of Health Science, The Lawrence W. and Marilyn W. Matteson Fund for Cancer Research, and the Kemper Marley Foundation, outside the submitted work. The LET calculation technology reported in this study has been licensed to .decimal LLC by Mayo Clinic. Robert H. Foote, MD, reports relevant financial activities from Elsevier, UpToDate, and Hitachi, Ltd, outside the submitted work; in addition, Dr Foote has a patent (US Patent No. 9,414,896) titled “Methods and Materials for Oral Stenting” with royalties paid to Mayo Clinic and Robert Foote. The authors have no additional conflicts to disclose.

**Funding:** This research was supported by Arizona Biomedical Research Commission Investigator Award, the Lawrence W. and Marilyn W. Matteson Fund for Cancer Research, and the Kemper Marley Foundation. Dr Wei Liu has a grant from the National Cancer Institute (NCI) Career Developmental Award K25CA168984.

**Ethical Approval:** This study was reviewed by the authors’ institutional research infrastructure and was determined to be exempt from IRB approval.

### References

1. Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated proton therapy. *Med Phys*. 2012;39:1079–91.
2. Liu W, Frank SJ, Li X, Li Y, Zhu RX, Mohan R. PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization. *Med Phys*. 2013;40:021709.
3. von Sonntag C. *The Chemical Basis of Radiation Biology*. London: Taylor & Francis; 1987.
4. von Sonntag C. Free-radical-induced DNA damage as approached by quantum-mechanical and Monte Carlo calculations: an overview from the standpoint of an experimentalist. *Adv Quantum Chem*. 2007;52:5–20.
5. Hirayama R, Ito A, Tomita M, Tsukada T, Yatagai F, Noguchi M, Matsumoto Y, Kase Y, Ando K, Okayasu R. Contributions of direct and indirect actions in cell killing by high-LET radiations. *Radiat Res*. 2009;171:212–8.
6. Ito A, Nakano H, Kusano Y, Hirayama R, Furusawa Y, Murayama C, Mori T, Katsumura Y, Shinohara K. Contribution of indirect action to radiation-induced mammalian cell inactivation: dependence on photon energy and heavy-ion LET. *Radiat Res*. 2006;165:703–12.
7. Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy: variations as a function of biological endpoint, dose, and linear energy transfer. *Phys Med Biol*. 2014;59:R419.
8. Unkelbach J, Botas P, Giantsoudi D, Gorissen BL, Paganetti H. Reoptimization of intensity modulated proton therapy plans based on linear energy transfer. *Int J Radiat Oncol Biol Phys*. 2016;96:1097–106.
9. Jones B, Underwood T, Dale R. The potential impact of relative biological effectiveness uncertainty on charged particle treatment prescriptions. *Br J Radiol*. 2011;84:S61–9.
10. Grassberger C, Tofimov A, Lomax A, Paganetti H. Variations in linear energy transfer within clinical proton therapy fields and the potential for biological treatment planning. *Int J Radiat Oncol Biol Phys*. 2011;80:1559–66.
11. Grassberger C, Paganetti H. Elevated LET components in clinical proton beams. *Phys Med Biol*. 2011;56:6677.
12. Gridley DS, Pecaut MJ, Mao XW, Wroe AJ, Luo-Owen X. Biological effects of passive versus active scanning proton beams on human lung epithelial cells. *Technol Cancer Res Treat*. 2015;14:81–98.
13. Wilkens J, Oelfke U. A phenomenological model for the relative biological effectiveness in therapeutic proton beams. *Phys Med Biol*. 2004;49:2811–25.
14. Carabe A, Moteabbed M, Depauw N, Schuermann J, Paganetti H. Range uncertainty in proton therapy due to variable biological effectiveness. *Phys Med Biol*. 2012;57:1159–72.
15. Wedenberg M, Lind BK, Hårdemark B. A model for the relative biological effectiveness of protons: the tissue specific parameter $\alpha/\beta$ of photons is a predictor for the sensitivity to LET changes. Acta Oncol. 2013;52:580–88.

16. McNamara AL, Schuemann J, Paganetti H. A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all published in vitro cell survival data. Phys Med Biol. 2015;60:8399–416.

17. An Y, Shan J, Patel SH, Wong W, Schild SE, Ding X, Bues M, Liu W. Robust intensity-modulated proton therapy to reduce high linear energy transfer in organs at risk. Med Phys. 2017;44:6138–47.

18. Grün R, Friedrich T, Krämmer M, Scholz M. Systematics of relative biological effectiveness measurements for proton radiation along the spread out Bragg peak: experimental validation of the local effect model. Phys Med Biol. 2017;62:890.

19. Paganetti H, Blakely E, Carabe-Fernandez A, Carlson DJ, Das IJ, Dong L, Grosshans D, Held KD, Mohan R, Moiseenko V. Report of the AAPM TG-256 on the relative biological effectiveness of proton beams in radiation therapy. Med Phys. 2019;46:e53–78.

20. Guan F, Peeler C, Bronk L, Geng C, Taleei R, Randeniya S, Ge S, Mirkovic D, Grosshans D, Mohan R. Analysis of the track-and-dose-averaged LET and LET spectra in proton therapy using the geant4 Monte Carlo code. Med Phys. 2015;42:6234–47.

21. Gentile MS, Yeap BY, Paganetti H, Goebel CP, Gaudet DE, Gallotto SL, Weyman EA, Morgan ML, MacDonald SM, Giantsoudi D. Brainstem injury in pediatric patients with posterior fossa tumors treated with proton beam therapy and associated dosimetric factors. Int J Radiat Oncol Biol Phys. 2018;100:719–29.

22. Underwood TSA, Grassberger C, Bass R, MacDonald SM, Meyersohn NM, Yeap BY, Jimenez RB, Paganetti H. Asymptomatic late-phase radiographic changes among chest-wall patients are associated with a proton RBE exceeding 1.1. Int J Radiat Oncol Biol Phys. 2018;101:809–19.

23. Peeler CR, Mirkovic D, Titt U, Blanchard P, Gunther JR, Mahajan A, Mohan R, Grosshans DR. Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. Radiother Oncol. 2016;121:395–401.

24. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26:3582–9.

25. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK. Radiation doses to structures within and adjacent to the larynx are correlated with long-term diet- and speech-related quality of life. Int J Radiat Oncol Biol Phys. 2007;68:750–7.

26. Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damen E, Van As CJ, Marsh R, Pameijer FA, Balm AJ. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys. 2004;60:1425–39.

27. Agostinelli S, Allison J, Amako Ka, Apostolakis J, Araujo H, Arce P, Asai M, Axen D, Banerjee S, Barrand G. GEANT4—a simulation toolkit. Nucl Instrum Methods Phys Res A. 2003;506:250–303.

28. Cortés-Giraldo M, Carabe A. A critical study of different Monte Carlo scoring methods of dose average linear-energy-transfer maps calculated in voxelized geometries irradiated with clinical proton beams. Phys Med Biol. 2015;60:2645.

29. Granville DA, Sawakuchi GO. Comparison of linear energy transfer scoring techniques in Monte Carlo simulations of proton beams. Phys Med Biol. 2015;60:N283.

30. Dahle TJ, Rykkveld AM, Stokkevåg CH, Mairani A, Görgen A, Edin NJ, Rørvik E, Fjæra LF, Malinen E, Ytre-Hauge KS. Monte Carlo simulations of a low energy proton beamline for radiobiological experiments. Acta Oncol. 2017;56:779–86.

31. Waters L, Hendricks J, McKinney G. Monte Carlo N-Particle Transport Code System for Multiparticle and High Energy Applications. Los Alamos, NM: Los Alamos National Laboratory; 2002.

32. Battistoni G, Broggi F, Brugger M, Campanella M, Carboni M, Cerutti F, Colleoni P, D’Ambrosio C, Empl A, Fassò A. The FLUKA code and its use in hadron therapy. Nuovo Cimento della Societa Italiana di Fisica C. 2008;31:69–75.

33. Kozłowska WS, Böhlen TT, Cuccagna C, Ferrari A, Fracchiolla F, Magro G, Mairani A, Schwarz M, Vlachoudis V, Georg D. FLUKA particle therapy tool for Monte Carlo independent calculation of scanned proton and carbon ion beam therapy. Phys Med Biol. 2019;64:075012.

34. Perl J, Shin J, Schümann J, Faddegon B, Paganetti H. TOPAS: an innovative proton Monte Carlo platform for research and clinical applications. Med Phys. 2012;39:6818–37.
35. Wan Chan Tseung H, Ma J, Beltran C. A fast GPU-based Monte Carlo simulation of proton transport with detailed modeling of nonelastic interactions. *Med Phys*. 2015;42(6 pt 1):2967–78.

36. Jia X, Schümann J, Paganetti H, Jiang SB. GPU-based fast Monte Carlo dose calculation for proton therapy. *Phys Med Biol*. 2012;57:7783.

37. Schiavi A, Senzacqua M, Pioli S, Mairani A, Magro G, Molinelli S, Ciocca M, Battistoni G, Patera V. Fred: a GPU-accelerated fast-Monte Carlo code for rapid treatment plan recalculation in ion beam therapy. *Phys Med Biol*. 2017;62:7482.

38. Souris K, Lee JA, Sterpin E. Fast multipurpose Monte Carlo simulation for proton therapy using multi- and many-core CPU architectures. *Med Phys*. 2016;43:1700–12.

39. Deng W, Younkin JE, Souris K, Huang S, Augustine K, Fatyga M, Ding X, Cohilis M, Bues M, Shan J. Integrating an open source Monte Carlo code “MCsquare” for clinical use in intensity-modulated proton therapy. *Med Phys*. 2020;47:2558–74.

40. Saini J, Maes D, Egan A, Bowen SR, St James S, Janson M, Wong T, Bloch C. Dosimetric evaluation of a commercial proton spot scanning Monte-Carlo dose algorithm: comparisons against measurements and simulations. *Phys Med Biol*. 2017;62:7659.

41. Lin L, Huang S, Kang M, Hiltunen P, Vanderstraeten R, Lindberg J, Siljamaki S, Wareing T, Davis I, Barnett A. A benchmarking method to evaluate the accuracy of a commercial proton monte carlo pencil beam scanning treatment planning system. *J Appl Clin Med Phys*. 2017;18:44–9.

42. Chih-Wei Chang SH, Joseph Harms, Jun Zhou, Rongxiao Zhang, Anees Dhabaan, Roelf Slopsema, Minglei Kang, Tian Liu, Mark McDonald, Katja Langen and Liyong Lin. A standardized commissioning framework of Monte Carlo dose calculation algorithms for proton pencil beam scanning treatment planning systems. *Med Phys*. 2020;47(4):1545–1557.

43. Buti G, Souris K, Montero AMB, Lee JA, Sterpin E. Towards fast and robust 4D optimization for moving tumors with scanned proton therapy. *Med Phys*. 2019;46:5434–43.

44. Ma J, Wan Chan Tseung HS, Herman MG, Beltran C. A robust intensity modulated proton therapy optimizer based on Monte Carlo dose calculation. *Med Phys*. 2018;45:4045–54.

45. Souris K, Montero AB, Janssens G, Di Perri D, Sterpin E, Lee JA. Technical note: Monte Carlo methods to comprehensively evaluate the robustness of 4D treatments in proton therapy. *Med Phys*. 2019;46:4676–84.

46. Chen Y, Ahmad S. Empirical model estimation of relative biological effectiveness for proton beam therapy. *Radiat Prot Dosimetry*. 2012;149:116–23.

47. Cirrone GAP, Cuttone G, Mazzaglia ES, Romano F, Sardina D, Agodi C, Attili A, Blancato AA, De Napoli M, Di Rosa F. Hadrontherapy: a Geant4-based tool for proton/ion-therapy studies. *Prog Nucl Sci Technol*. 2011;2:207–12.

48. Perles L, Mirkovic D, Anand A, Titt U, Mohan R. LET dependence of the response of EBT2 films in proton dosimetry modeled as a bimolecular chemical reaction. *Phys Med Biol*. 2013;58:8477.

49. Sawakuchi GO, Sahoo N, Gasparian PB, Rodriguez MG, Archambault L, Titt U, Yukiha EG. Determination of average LET of therapeutic proton beams using Al2O3: C optically stimulated luminescence (OSL) detectors. *Phys Med Biol*. 2010;55:4963.

50. Granville DA, Sahoo N, Sawakuchi GO. Calibration of the Al2O3: C optically stimulated luminescence (OSL) signal for linear energy transfer (LET) measurements in therapeutic proton beams. *Phys Med Biol*. 2014;59:4295.

51. Wilkens JJ, Oelfke U. Analytical linear energy transfer calculations for proton therapy. *Med Phys*. 2003;30:806–15.

52. Wilkens JJ, Oelfke U. Three-dimensional LET calculations for treatment planning of proton therapy. *Z Med Phys*. 2004;14:41–6.

53. Sanchez-Parcerisa D, Cortés-Giraldo M, Dolney D, Kondrla M, Fager M, Carabe A. Analytical calculation of proton linear energy transfer in voxelized geometries including secondary protons. *Phys Med Biol*. 2016;61:1705.

54. Marsolat F, De Marzi L, Pouzoulet F, Mazal A. Analytical linear energy transfer model including secondary particles: calculations along the central axis of the proton pencil beam. *Phys Med Biol*. 2016;61:740.

55. Hirayama S, Matsuura T, Ueda H, Fujiy H, Fujiy T, Takao S, Miyamoto N, Shimizu S, Fujimoto R, Umegaki K. An analytical dose-averaged LET calculation algorithm considering the off-axis LET enhancement by secondary protons for spot-scanning proton therapy. *Med Phys*. 2018;45:3404–16.
56. Deng W, Ding X, Younkin JE, Shen J, Bues M, Schild SE, Patel SH, Liu W. Hybrid 3D analytical linear energy transfer calculation algorithm based on precalculated data from Monte Carlo simulations. *Med Phys*. 2020;47:745–52.

57. Bertolalet A, Cortés-Giraldo M, Carabe-Fernandez A. On the concepts of dose-mean lineal energy, unrestricted and restricted dose-averaged LET in proton therapy. *Phys Med Biol*. 2020;65:075011.

58. Kellerer AM. Fundamentals of microdosimetry. *Dosimetry Ionizing Radiat*. 1985;1:77–162.

59. Hawkins R. A microdosimetric-kinetic model of cell death from exposure to ionizing radiation of any LET, with experimental and clinical applications. *Int J Radiat Biol*. 1996;69:739–55.

60. Hawkins RB. A microdosimetric-kinetic model for the effect of non-Poisson distribution of lethal lesions on the variation of RBE with LET. *Radiat Res*. 2003;160:61–9.

61. Kase Y, Kanai T, Matsufuji N, Furusawa Y, Elsasser T, Scholz M. Biophysical calculation of cell survival probabilities using amorphous track structure models for heavy-ion irradiation. *Phys Med Biol*. 2007;53:37.

62. Kase Y, Yamashita W, Matsufuji T, Takada K, Sakae T, Furusawa Y, Yamashita H, Murayama S. Microdosimetric calculation of relative biological effectiveness for design of therapeutic proton beams. *J Radiat Res*. 2013;54:485–93.

63. Bertolet A, Baratto-Roldán A, Cortés-Giraldo M, Carabe-Fernandez A. Segment-averaged LET concept and analytical calculation from microdosimetric quantities in proton radiation therapy. *Med Phys*. 2019;46:4204–14.

64. Bertolet A, Cortés-Giraldo M, Souris K, Carabe A. A kernel-based algorithm for the spectral fluence of clinical proton beams to calculate dose-averaged LET and other dosimetric quantities of interest. *Med Phys*. 2020;47:2495–505.

65. Newpower M, Patel D, Bronk L, Guan F, Chaudhary P, McMahon SJ, Prise KM, Schettino G, Grosshans DR, Mohan R. Using the proton energy spectrum and microdosimetry to model proton relative biological effectiveness. *Int J Radiat Oncol Biol Phys*. 2019;104:316–24.

66. Perales Á, Baratto-Roldán A, Kimstrand P, Cortés-Giraldo MA, Carabe A. Parameterising microdosimetric distributions of mono-energetic proton beams for fast estimates of yD and y. *Biomed Phys Eng Express*. 2019;5:045014.

67. Belli M, Campa A, Ermolli I. A semi-empirical approach to the evaluation of the relative biological effectiveness of therapeutic proton beams: the methodological framework. *Radiat Res*. 1997;148:592–8.

68. Tilly N, Johansson J, Isacsson U, Medin J, Blomquist E, Grusell E, Glimelius B. The influence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer. *Phys Med Biol*. 2005;50:2765–77.

69. Jones B. Towards achieving the full clinical potential of proton therapy by inclusion of LET and RBE models. *Cancers*. 2015;7:460–80.

70. Mairani A, Dokic I, Magro G, Tessonnier T, Bauer J, Bohlen TT, Ciocca M, Ferrari A, Sala PR, Jakel O, Debus J, Haberer T, Abdollahi A, Parodi K. A phenomenological relative biological effectiveness approach for proton therapy based on an improved description of the mixed radiation field. *Phys Med Biol*. 2017;62:1378–95.

71. Rørvik E, Thörnqvist S, Stokkevåg CH, Dahle TJ, Fjæra LF, Ytre-Hauge KS. A phenomenological biological dose model for proton therapy based on linear energy transfer spectra. *Med Phys*. 2017;44:2586–94.

72. Frese MC, Wilkens JJ, Huber PE, Jensen AD, Oelfke U, Taheri-Kadkhoda Z. Application of constant vs. variable relative biological effectiveness in treatment planning of intensity-modulated proton therapy. *Int J Radiat Oncol Biol Phys*. 2011;79:80–8.

73. Wan Chan Tseung HS, Ma J, Kreofsky CR, Ma DJ, Beltran C. Clinically applicable Monte Carlo–based biological dose optimization for the treatment of head and neck cancers with spot-scanning proton therapy. *Int J Radiat Oncol Biol Phys*. 2016;95:1535–43.

74. Elsässer T, Krämer M, Scholz M. Accuracy of the local effect model for the prediction of biologic effects of carbon ion beams in vitro and in vivo. *Int J Radiat Oncol Biol Phys*. 2008;71:866–72.

75. Elsässer T, Scholz M. Cluster effects within the local effect model. *Radiat Res*. 2007;167:319–29.

76. Elsässer T, Weyrather WK, Friedrich T, Durante M, Iancu G, Krämer M, Kragl G, Brons S, Winter M, Weber K-J, Scholz M. Quantification of the relative biological effectiveness for ion beam radiotherapy: direct experimental comparison of proton and carbon ion beams and a novel approach for treatment planning. *Int J Radiat Oncol Biol Phys*. 2010;78:1177–83.

77. Carlson DJ, Stewart RD, Semenenko VA, Sandison GA. Combined use of Monte Carlo DNA damage simulations and deterministic repair models to examine putative mechanisms of cell killing. *Radiat Res*. 2008;169:447–59.
78. Rørvik E, Fjæra LF, Dahle TJ, Dale JE, Engeseth GM, Stokkevåg CH, Thørnqvist S, Ytre-Hauge KS. Exploration and application of phenomenological RBE models for proton therapy. *Phys Med Biol*. 2018;63:185013.
79. Fossum CC, Beltran CJ, Whitaker TJ, Ma DJ, Foote RL. Biological model for predicting toxicity in head and neck cancer patients receiving proton therapy. *Int J Part Ther*. 2017;4:18–25.
80. Giantsoudi D, Adams J, MacDonald S, Paganetti H. Can differences in linear energy transfer and thus relative biological effectiveness compromise the dosimetric advantage of intensity-modulated proton therapy as compared to passively scattered proton therapy? *Acta Oncol*. 2018;57:1259–64.
81. Carabe A, Espana S, Grassberger C, Paganetti H. Clinical consequences of relative biological effectiveness variations in proton radiotherapy of the prostate, brain and liver. *Phys Med Biol*. 2013;58:2103–17.
82. Giovannini G, Böhlen T, Cabal G, Bauer J, Tessonnier T, Frey K, Debus J, Mairani A, Parodi K. Variable RBE in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios. *Radiat Oncol*. 2016;11:68.
83. Giantsoudi D, Sethi RV, Yeap BY, Eaton BR, Ebb DH, Caruso PA, Rapalino O, Chen YE, Adams JA, Yock TI, Tarbell NJ, Paganetti H, MacDonald SM. Incidence of CNS Injury for a cohort of 111 patients treated with proton therapy for medulloblastoma: LET and RBE associations for areas of injury. *Int J Radiat Oncol Biol Phys*. 2016;95:287–96.
84. Yepes P, Adair A, Frank SJ, Grosshans DR, Liao Z, Liu A, Mirkovic D, Poinisch F, Titt U, Wang Q, Mohan R. Fixed-versus variable-RBE computations for intensity modulated proton therapy. *Adv Radiat Oncol*. 2019;4:156–67.
85. Hirayama S, Matsuura T, Yasuda K, Takao S, Fujii T, Miyamoto N, Umegaki K, Shimizu S. Difference in LET-based biological doses between IMPT optimization techniques: robust and PTV-based optimizations. *J Appl Clin Med Phys*. 2020;21:42–50.
86. Öden J, Eriksson K, Toma-Dasu I. Incorporation of relative biological effectiveness uncertainties into proton plan robustness evaluation. *Acta Oncol*. 2017;56:769–78.
87. Oden J, Eriksson K, Toma-Dasu I. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy. *Med Phys*. 2017;44:810–22.
88. Underwood T, Giantsoudi D, Moteabbed M, Zietman A, Efstathiou J, Paganetti H, Lu HM. Can we advance proton therapy for prostate considering alternative beam angles and relative biological effectiveness variations when comparing against intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys*. 2016;95:454–64.
89. Ytre-Hauge KS, Fjæra LF, Rørvik E, Dahle TJ, Dale JE, Pilskog S, Stokkevåg CH. Inter-patient variations in relative biological effectiveness for cranio-spinal irradiation with protons. *Sci Rep*. 2020;10:6212.
90. Sethi RV, Giantsoudi D, Raiford M, Malhi I, Niemierko A, Rapalino O, Caruso P, Yock TI, Tarbell NJ, Paganetti H, McDonald SM. Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses. *Int J Radiat Oncol Biol Phys*. 2014;88:655–63.
91. Bolsi A, Placidi L, Pica A, Ahlhelm F, Walser M, Lomax T, Weber DC. Pencil beam scanning proton therapy for the treatment of craniopharyngioma complicated with radiation-induced cerebral vasculopathies: a dosimetric and linear energy transfer (LET) evaluation. *Radiother Oncol*. 2020;149:197–204.
92. Öden J, Toma-Dasu I, Witt Nyström P, Traneus E, Dasu A. Spatial correlation of linear energy transfer and relative biological effectiveness with suspected treatment-related toxicities following proton therapy for intracranial tumors. *Med Phys*. 2020;47:342–51.
93. Eulitz J, Lutz B, Wohlfahrt P, Dutz A, Enghardt W, Karpowitz C, Krause M, Troost EGC, Lühr A. A Monte Carlo based radiation response modelling framework to assess variability of clinical RBE in proton therapy. *Phys Med Biol*. 2019;64:225020.
94. Eulitz J, Troost EGC, Raschke F, Schulz E, Lutz B, Dutz A, Löck S, Wohlfahrt P, Enghardt W, Karpowitz C, Krause M, Lühr A. Predicting late magnetic resonance image changes in glioma patients after proton therapy. *Acta Oncol*. 2019;58:1536–9.
95. Bahn E, Bauer J, Harrabi S, Herfarth K, Debus J, Alber M. Late contrast enhancing brain lesions in proton-treated patients with low-grade glioma: clinical evidence for increased periventricular sensitivity and variable RBE. *Int J Radiat Oncol Biol Phys*. 2020;107:571–8.
96. Bassler N, Jakel O, Sondergaard CS, Petersen JB. Dose- and LET-painting with particle therapy. *Acta Oncol*. 2010;49:1170–6.
97. Giantsoudi D, Grassberger C, Craft D, Niemierko A, Trofimov A, Paganetti H. Linear energy transfer-guided optimization in intensity modulated proton therapy: feasibility study and clinical potential. *Int J Radiat Oncol Biol Phys*. 2013;87:216–22.

98. Cao W, Khabazian A, Yepes PP, Lim G, Poenisch F, Grosshans DR, Mohan R. Linear energy transfer incorporated intensity modulated proton therapy optimization. *Phys Med Biol*. 2017;63:015013.

99. Bai X, Lim G, Wieser H-P, Bangert M, Grosshans D, Mohan R, Cao W. Robust optimization to reduce the impact of biological effect variation from physical uncertainties in intensity-modulated proton therapy. *Phys Med Biol*. 2019;64:025004.

100. Bai X, Lim G, Grosshans D, Mohan R, Cao W. A biological effect-guided optimization approach using beam distal-edge avoidance for intensity-modulated proton therapy. *Med Phys*. 2020;47:3816–25.

101. Inaniwa T, Kanematsu N, Noda K, Kamada T. Treatment planning of intensity modulated composite particle therapy with dose and linear energy transfer optimization. *Phys Med Biol*. 2017;62:5180–97.

102. Liu C, Patel SH, Shan J, Schild SE, Vargas C, Wong WW, Ding X, Bues M, Liu W. Robust optimization for intensity modulated proton therapy to redistribute high linear energy transfer from nearby critical organs to tumors in head and neck cancer. *Int J Radiat Oncol Biol Phys*. 2020;107:181–93.

103. Traneus E, Ödén J. Introducing proton track-end objectives in intensity modulated proton therapy optimization to reduce linear energy transfer and relative biological effectiveness in critical structures. *Int J Radiat Oncol Biol Phys*. 2019;103:747–57.

104. Zaghian M, Lim G, Liu W, Mohan R. An automatic approach for satisfying dose-volume constraints in linear fluence map optimization for IMPT. *J Cancer Ther*. 2014;5:198–207.

105. Zhang P, Fan N, Shan J, Schild SE, Bues M, Liu W. Mixed integer programming with dose-volume constraints in intensity-modulated proton therapy. *J Appl Clin Med Phys*. 2017;18:29–35.

106. Liu W, Liao Z, Schild SE, Liu Z, Li H, Li Y, Park PC, Li X, Stoker J, Shen J. Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. *Pract Radiat Oncol*. 2015;5:e77–86.

107. An Y, Liang JM, Schild SE, Bues M, Liu W. Robust treatment planning with conditional value at risk chance constraints in intensity-modulated proton therapy. *Phys Med Biol*. 2017;44:28–36.

108. Chen W, Unkelbach J, Trofimov A, Madden T, Kooy H, Bortfeld T, Craft D. Including robustness in multi-criteria optimization for intensity-modulated proton therapy plans for lung cancer. *Int J Radiat Oncol Biol Phys*. 2018;101:479–89.

109. Liu W, Mohan R, Park P, Liu Z, Li H, Li X, Wu R, Sahoo N, Dong L, Zhu XR, Grosshans DR. Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers. *Pract Radiat Oncol*. 2014;4:384–91.

110. Liu W, Schild SE, Chang JY, Liao ZX, Korte S, Shen JJ, Ding XN, Hu YL, Kang YX, Keole SR, Sio TT, Wong WW, Sahoo N, Bues M, Liu W. Impact of spot size and spacing on the quality of robustly optimized intensity modulated proton therapy plans for lung cancer. *Int J Radiat Oncol Biol Phys*. 2018;101:479–89.

111. Liu W, inventor. System and method for robust intensity-modulated proton therapy planning. September 2, 2014.

112. Liu W. Robustness quantification and robust optimization in intensity-modulated proton therapy. In: Rath A, Sahoo N, eds. *Particle Radiotherapy: Emerging Technology for Treatment of Cancer*. Springer; 2015:139–56.

113. Liu W, Frank SJ, Li X, Li Y, Park P, Dong L, Zhu XR, Mohan R. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. *Med Phys*. 2013;40:051711.

114. Liu W, Li Y, Li X, Cao W, Zhang X. Influence of robust optimization in intensity-modulated proton therapy with different dose delivery techniques. *Med Phys*. 2012;39:3089–101.

115. Liu W, Mohan R, Park P, Liu Z, Li H, Li X, Li Y, Wu R, Sahoo N, Dong L, Zhu XR, Grosshans DR. Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers. *Pract Radiat Oncol*. 2014;4:384–91.

116. Liu W, Schild SE, Chang JY, Liao ZX, Chang YH, Wen ZF, Shen JJ, Stoker JB, Ding XN, Hu YL, Sahoo N, Herman MG, Vargas C, Keole S, Wong W, Bues M. Exploratory study of 4D versus 3D robust optimization in intensity modulated proton therapy for lung cancer. *Int J Radiat Oncol Biol Phys*. 2016;95:523–33.

117. Pflugfelder D, Wilkens JJ, Oelfke U. Worst case optimization: a method to account for uncertainties in the optimization of intensity modulated proton therapy. *Phys Med Biol*. 2008;53:1689–700.
118. Shan J, An Y, Bues M, Schild SE, Liu W. Robust optimization in IMPT using quadratic objective functions to account for the minimum MU constraint. *Med Phys*. 2018;45:460–9.

119. Shan J, Sio TT, Liu C, Schild SE, Bues M, Liu W. A novel and individualized robust optimization method using normalized dose interval volume constraints (NDIVC) for intensity-modulated proton radiotherapy. *Med Phys*. 2019;46:382–93.

120. Unkelbach J, Alber M, Bangert M, Bokrantz R, Chan TCY, Deasy JO, Fredriksson A, Gorissen BL, van Herk M, Liu W, Mahmoudzadeh H, Nohadani O, Siebers JV, Witte M, Xu H. Robust radiotherapy planning. *Phys Med Biol*. 2018;63:22TR02.

121. Unkelbach J, Bortfeld T, Martin BC, Soukup M. Reducing the sensitivity of IMPT treatment plans to setup errors and range uncertainties via probabilistic treatment planning. *Med Phys*. 2009;36:149–63.

122. Unkelbach J, Chan TCY, Bortfeld T. Accounting for range uncertainties in the optimization of intensity modulated proton therapy. *Phys Med Biol*. 2007;52:2755–73.

123. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. *Int J Radiat Oncol Biol Phys*. 2010;76:S3–9.